We tested the abilities of two potent non-N methyl-D-aspartate (non-NMDA) glutamate antagonists [2, 3-dihydroxy -6-nitro-7 -sulfamoy Ibenzo(F)quinoxaline (NBQX)] and [1-( 4-aminophenyl)-4-methyl-7 ,8methylene-dioxy-5H-2,3-benzodiazepine hydrochloride (GYKI 52466)] to reduce neocortical infarction following 2 h of transient middle cerebral artery occlusion in a hy pertensive stroke model in the rat and compared these effects against, and in combination with, a potent NMDA antagonist [( + )-5-methyl-IO, ll-dihydro-5H-dibenzo [a,d]cyc1ohepten-5,10-amine maleate (MK-80 1)]. In Expt. I, an already established cytoprotective dose of Na + -NBQX (30 mg/kg i.p. x 3) was compared with saline (1 ml), the NMDA antagonist MK-801 (1 mg/kg i.p. x 3), and a combination of the same doses of both NBQX and MK-801. Initial doses were delayed to 90 min following occlusion with subsequent injections at the time of reper fusion and 30 min following reperfusion. Saline-treated rats sustained 181 ± 32 mm 3 (n = 15) of neocortical in farction (mean ± SD). This was significantly reduced by NBQX to 137 ± 25 mm 3 (n = 15, p < 0.05) of damage.
proved to be cytoprotective when given with a 9O-min delay. In Expt. 2, NBQX (30 mg/kg) was dissolved (6 mg/ml) in 5% dextrose and compared with both saline and dextrose (1.2 ml) i. v. infusions given over a 4-h period starting I h after occlusion. Saline-treated rats had a mean infarct of 183 ± 27 mm 3 (n = 6), dextrose-treated had 200 ± 30 mm 3 (n = 9), while for NBQX-treated rats it was reduced to 129 ± 60 mm 3 (n = 10, p < 0.05). Intravenous NBQX precipitated into the renal tubules, causing neph rotoxicity. In Expt. 3, rats were given either saline (1 ml i.p.) or GYKI 52466 (10 mg/kg i.p.) at 30 and 90 min following occlusion and at 30, 90, and 150 min following reperfusion. Saline-treated rats sustained 187 ± 27 mm 3 of neocortical infarction (n = 7), while those treated with GYKI 52466 were protected, with 139 ± 38 mm 3 of in farction (n = 7, p < 0.05). A clinically useful role for a-amino-3-hydroxy-5-methyl-4-isoxazole propionate an tagonists in embolic stroke is envisaged if nontoxic drugs can be developed, since cerebroprotection was achieved with delayed treatment with both of these lead com pounds. Key Words: Cerebral blood flow-Excito toxicity-Glutamate-N ephrotoxicity-Stroke.
tion of glutamate receptors coupled to ion channels, resulting in a lethal calcium ion influx (Choi, 1987) .
Glutamate antagonists have therefore been inten sively studied in animal models of ischemia in the hope that a therapeutic role for this class of agent could be defined. Early reports that detected a po tent neuroprotective role for both the competitive (Simon et aI., 1984) and the noncompetitive (Gill et aI., 1987) N-methyl-D-aspartate (NMDA) glutamate antagonists have not been universally supported, leading to suggestions that while NMDA antago nists are unable to prevent selective neuronal death following brief severe forebrain ischemia (Buchan et aI., 1991b; Nellgard et al., 1991) , they may be beneficial in situations of partial energy failure such as focal ischemia (Siesjo and Bengtsson, 1989) .
While NMDA pretreatment with antagonists, in particular ( + )-5-methyl-l 0, II-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-amine maleate (MK-801), had been judged effective in its ability to attenuate infarct volume in focal ischemia (for review see Buchan, 1990) , it has been relatively less protective in models employing hypertensive rats (Buchan et aI., 1992b; Roussel et aI., 1992) and in experimental ischemia models using thrombotic (Yao et aI., 1993) and embolic (Memezawa et aI., 1993) stroke. Two antagonists, 2,3-dihydroxy-6-nitro-7 -sulfa moylbenzo(F)quinoxaline (NBQX) (Sheardown et aI., 1990) and the benzodiazepine derivative 1-(4aminophenyl)-4-methyl-7,8-methylene-dioxy-5H-2,3-benzodiazepine hydrochloride (GYKI 52466) (Tarnawa et aI., 1990 (Tarnawa et aI., , 1992 Ouardouz and Durand, 1991) , selectively block a-amino-3-hydroxy-5methyl-4-isoxazole propionate (AMPA) receptors (Honore et aI., 1988) and make possible the evalu ation of the role that the non-NMDA glutamate re ceptors play in mediating ischemic brain injury. Se lective for the AMP A receptor, and not active at the glycine site of the NMDA receptor or the metabo tropic receptor (Suzdak et aI., 1990) , NBQX has proven to be robustly effective as a neuronal cyto protectant in the wake of transient forebrain isch emia for hippocampal CAl neurons (Sheardown et aI., 1990; Buchan et aI., 1991a; Diemer et aI., 1992) and against the loss of cortical and striatal neurons (Nellgard and Wieloch, 1992) . In addition, NBQX can also reduce glutamate-mediated brain edema (Westgren and Johansson, 1992) . GYKI 52466, which is a potent anticonvulsant against AMPA induced seizures with a similar anticonvulsant pro file to NBQX (Chapman et aI., 1991) and appears to act, in comparison with NBQX, by a novel noncom petitive mechanism (Donevan and Rogawski, 1993) , is also capable of reducing neuronal injury following forebrain ischemia (LePeillet et aI., 1992) . Particu larly promising is the observation that these drugs can be given successfully even after a substantial postischemic delay Li and Buchan, 1993) .
The present study was therefore undertaken to see if the neuroprotective properties of these two different AMP A antagonists would extend to tran sient focal ischemia and to compare the effects of NBQX and GYKI 52466, since these lead or proto type compounds are likely to be forerunners of a series of novel AMPA antagonists. We have em ployed a rat model of temporary middle cerebral artery (MCA) occlusion in which we have previ ously demonstrated highly consistent volumes of neocortical infarction (Buchan et aI., 1992b) , achieved by using spontaneously hypertensive rats J Cereb Blood Flow Metab, Vol. 14, No.2, 1994 (SHRs) as opposed to normotensive rats (Duverger and MacKenzie, 1988) . In distinction to many of the positive studies with NMDA antagonists (Buchan, 1990) , we have employed a delayed treatment par adigm for i.p. NBQX and compared the results to either delayed MK-801 therapy or a combination of both MK-801 and (an established cytoprotective i.p. dose of) NBQX given late (Expt. 1). Using the same experimental model and a similar delayed treatment paradigm, we have also tested the i.v. administration of NBQX (Expt. 2) and the noncom petitive AMPA antagonist GYKI 52466 (Expt. 3). Provisional data showing a cytoprotective effect dissociated from blood flow changes in focal isch emia with delayed treatment of NBQX alone have been reported (Buchan et aI., 1991c) .
MATERIALS AND METHODS

Focal ischemia
Fasted male SHRs weighing 225-250 g were initially anesthetized with 3% halothane and subsequently main tained with 1-2% (in an O2 28%/N2 70% mixture). The tail artery was cannulated to monitor mean arterial pressure and arterial blood gases. The right common carotid artery (CCA) was isolated and a loose ligature placed around it. The temporalis muscle was excised and a 2-mm burr hole drilled 2-3 mm rostral to the fusion of the zygomatic arch with the squamosal bone, exposing the right MCA where it crosses the rhinal fissure (Coyle, 1982; Brint et al., 1988) . Regional CBF (rCBF) was recorded using laser Doppler flowmetry (Dirnagl et al., 1989) in two locations. Burr holes were drilled, one 4 mm dorsal to the exposure for the MCA to measure the ischemic core rCBF and the second 3 mm posterior and 5 mm lateral to bregma to measure the penumbral rCBF (Buchan et al., 1992b) . The dura was not breached, and the flow probe was advanced to the dural surface without indenting the underlying cor tex. Changes in rCBF were recorded as relative flow, calculated from preocclusion baseline flows and ex pressed as a percentage of baseline (Dirnagl et aI., 1989) .
Anesthetized rats had their arterial blood pressure, blood gases, and rCBF measured, and then the CCA was permanently occluded and the MCA temporarily oc cluded with a Codman no. 1 prototype aneurysm clip. Postocclusion rCBF was remeasured prior to closing the wound and inftltrating it with 2% lidocaine. The animals were returned to their cages and body temperature was controlled at 37.soC.
Study design and experimental paradigms
Three separate but complementary experiments were performed. In the first experiment, we compared a known i.p. cytoprotective dose of NBQX (Buchan et aI., 1991a) against both saline and MK-801 and, in addition, tested the "cocktail" of the same dose of NBQX in combination with MK-801 with all treatments initiated after a 90-min delay. In the second experiment, we slowly infused NBQX i. v. for 4 h starting at 60 min into ischemia to see how this compared with the improved outcome following i.p. injections. The third experiment utilized known cy-toprotective doses of GYKI 52466 (LePeillet et al., 1992; Smith and Meldrum, 1992) , using a delayed treatment paradigm in transient focal ischemia. All the experiments involved 2 h of transient focal ischemia followed by 22 h of reperfusion in SHRs.
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Times of dosing Experiment 1. After 90 min of ischemia, the SHRs ran domly received the first i.p. injection of either 1 ml saline (n = 15) or 30 mg/kg of the sodium salt of NBQX (7.5 mg dissolved in 1 ml of sterile water; n = 15). At 120 min after the onset of ischemia following reanesthesia, blood pressure, blood gases, and rCBF were redetermined prior to the removal of the MCA clip and the restoration of circulation. At this time a second i.p. dose of either saline or NBQX was given. The rCBF was remeasured within 10 min of reperfusion and following this the wounds were closed, anesthesia was once again discontinued, and the animals were returned to their cages with their tempera tures maintained. A third dose of either saline or NBQX was given 30 min following the onset of reperfusion. A third group of animals were given i.p. MK-801 (1 mg/kg x 3) at the same times, i.e., 90 and 120 min of ischemia and 30 min following reperfusion (n = 11). A fourth group received three doses of a combination of both i.p. NBQX (30 mg/kg x 3) and i.p. MK-801 (1 mg/kg x 3) at the same times as described (i.e., following 90 and 120 min of isch emia and 30 min of reperfusion) (n = 6).
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Animals were infused i.v. over a period of 4 h starting 1 h after the time of MCA occlusion, with saline (n = 6), 5% dextrose (n = 9), or the sodium salt of NBQX (30 mg/kg, 6 mg/ml in 5% dextrose) (n = 10). The NBQX had to be dissolved in 5% dextrose to infuse it i.v. as the low osmolality «100 mOsmollL) with it dissolved in sterile water (as for the i.p. injection) precluded intra vascular administration.
Times of dosing 1 1 1 1 1 1 2 3 4 5 Experiment 3. Animals received delayed treatment with either 1 ml saline (n = 7) or GYKI 52466 (10 mg/kg x 5; n = 7) i.p. A total of five doses were given, one each at 30 and 90 min after occlusion and at 30, 90, and 150 min after reperfusion.
Neuropathological analysis
Twenty-four hours following the onset of ischemia (i.e., 22 h after reperfusion), all animals were reanesthe-tized, blood gases and rCBF were redetermined, and then the rats were decapitated so that the brains could be re moved and frozen in isopentane, cooled on dry ice. Twenty-micron-thick sections were cut at -20°C, with one section saved at 500-lLm intervals, and stained with hematoxylin and eosin. Pannecrotic tissue was readily distinguished from intact brain, and the area of infarcted neocortex was traced on an image analyzer, using an im age-processing system (Image Pro II; Media Cybernetics, Silver Spring, MD, U.S.A.), but without knowledge as to the identity of the treatment groups. Infarct areas of each section were traced and a total infarct volume was calcu lated by summing the infarcted area of sequential sections and multiplying by the interval thickness between sec tions. Although in some animals, ischemic damage in volved a narrow crescent of dorsolateral striatum, only neocortical infarction was measured (Brint et al., 1988) .
Statistical analysis
Student's t tests for unpaired data were used to analyze differences in the physiological variables, including blood gases and rCBF. Comparisons between infarct sizes for different treatment groups were by analysis of variance, followed by a post hoc Tukey procedure for multiple com parisons (for Expts. 1 and 2) and a two-tailed unpaired Student's t test (for Expt. 3) (Zar, 1984) . A p value of <0.05 determined significance. Data are expressed as means ± SD. An a priori sample size calculation using data derived from the model (Buchan et al., 1992b) pre dicted six animals per groups would be needed to exclude a type II error, looking for a 30% difference, a = 0.5, 13
These experiments were done with the approval of the Animal Care Committee of the Ottawa Civic Hospital, and the animals were cared for according to guidelines published by the National Institutes of Health and the Canadian Council on Animal Care.
RESULTS
Morbidity and mortality
No animals were lost prior to death, although i. v. (as compared with i.p.) administration of NBQX did result in a heavy urinary precipitate with resulting nephrotoxic injury (see following discussion). Both NBQX and MK-801 had a mild sedative effect, al though this was exaggerated in those animals re ceiving the combination of treatments. GYKI 52466 had relatively little sedative effect and no observed toxicity.
Nephrotoxicity
In a pilot study in which NBQX was administered i. v. dissolved in sterile water in the same concen trations as used for i.p. administration (A. M. Buchan, unreported data), there was intravascular precipitation and, because of low osmolality « 100 mOsmoIlL), evidence of hemolysis and infarction to renal parenchyma. We therefore infused the NBQX, dissolved in dextrose 5% (255 mOsmoIlL), with concurrent controls receiving identical vol-
.1 , ,. urnes of dextrose 5% i.v. All rats given either i.p. NBQX (dissolved in sterile water) or i.v. NBQX (dissolved in dextrose 5%) rapidly excreted bright yellow-colored urine, but in i. v. treated rats, there was a particularly heavy sediment of NBQX in the urine. In Fig. lA , a slice through the medulla and cortex of the kidney is seen that shows crystals of NBQX deposited in the medulla. Under light mi croscopy ( Fig. lB) , negative birefringent crystals intraluminally were demonstrated in the distended tubules of the tips of the medullary pyramids, but relatively normal-appearing glomeruli, proximal and distal tubules, and interstitium of the renal cor tex. NBQX has crystallized and precipitated in traluminally in the loops of Henle where the med ullary interstitium is hypertonic. In some of the rats treated i. v. that were kept alive for longer periods (such as 7 days following global ischemia) (Li and Buchan, 1993) , there was evidence of renal failure with uremia (increased blood urea nitrogen), and on examination of the kidneys in chronically surviving animals there was renal atrophy. Six of 10 animals J Cereb Blood Flow Metab, Vol. 14, No. 2, 1994 in this experiment had to be killed early because of renal impairment (Li and Buchan, 1993) .
Physiological variables
In all three experiments, anesthesia was i n sti tuted prior to physiological and cerebral perfusion measurements. The addition of NBQX, MK-801, NBQX + MK-801, or GYKI 52466 had no adverse effects on blood pressure, arterial blood gases, or our ability to maintain body temperature. Arterial CO 2 levels, which tend to be higher in SHRs, were slightly, but not significantly, higher during isch emia in those animals treated with both MK-801 and NBQX (Table 1) .
CBFs
Core cortical ischemia rCBFs as a percentage of baseline measurements were very similar in all an imals at the start and finish of the 2 h of ischemia. Prompt and continued reperfusion was obtained for all groups (Table 2) . GYKI 52466-treated rats had an increase in rCBF to 17 ± 6% versus 8 ± 5% for saline-treated rats (p < 0.05) at the end of 2-h isch- BP, mean arterial blood pressure; N/A, not available; for other abbreviations see the text. There were no statistically significant differences. emia, just prior to reperfusion, suggesting that GYKI 52466 did partially attenuate the latter half of the ischemic insult.
Neuropathology
All animals had reasonably consistent patterns of infarction in the dorsolateral frontoparietal neocor tex, which were quantitated and reported as mean ± SD (mm3) infarct volumes for each group. In the three saline control groups, the means and the SDs were very consistent (181 ± 32, 183 ± 27, and 187 ± 27 mm3), displaying less variability than we had pre dicted a priori for our sample size calculations. A post hoc power analysis indicated that with six ani mals per group, we would have been able to detect a 15% difference (where one existed), with an u of 0.05 and power of 80%.
Expt. 1. Delayed administration of NBQX i.p. significantly reduced the cortical infarct size. Sa-line-treated animals sustained a mean ± SD infarct of 181 ± 32 mm3 (n = 15), while those treated with i.p. NBQX had 137 ± 25 mm 3 infarction (n = 15, p < 0.05) (Fig. 2) . Neither delayed MK-801-treated animals with a mean cortical infarction of 170 ± 33 mm3 (n = 11), nor those given the combination of NBQX and MK-801 with infarction of 169 ± 20 mm3 (n = 6), had any significant reduction of injury. Combining the drugs attenuated the protective re sponse of i.p. NBQX treatment alone (Table 3 , Expt. 1; Fig. 2) .
Expt. 2. Intravenous saline resulted in a mean infarct size of 183 ± 27 mm3 (n = 6). There was no difference in infarct volume when i. v. dextrose was given (200 ± 30 mm3; n = 9), but there was a sig nificant reduction in the volume of infarction in those animals infused following 60 min of ischemia with i.v. NBQX sustaining 129 ± 60 mm3 (n = 10) of neocortical infarction (p < 0.05) ( Table 3 , Expt. 2). There was a clear-cut reduction in the size of the infarct for 5 of the 10 experimental rats (Fig. 3) . In previous studies with i. v. NBQX administered in a similar way, i.e., with dextrose 5% following global ischemia, we have found a similar lack of consis tency in the cytoprotection as compared with that achieved with i.p. NBQX administration (Li and Buchan, 1993) .
Expt. 3. GYKI 52466 given i.p. starting 30 min after MCA occlusion resulted in a significant reduc tion of infarction (139 ±38 mm3; n = 7) as com pared with that of the saline controls (187 ± 27 mm3; n = 7, p < 0.05) ( Table 3 , Expt. 3). This reduction in injury is similar in magnitude to that obtained with NBQX, but may in part be related to a small improvement in intraischemic rCBF toward the end of the ischemic insult, an effect not seen with NBQX (Table 2) .
DISCUSSION
These data demonstrate that delayed treatment with both the non-NMDA or AMPA antagonists NBQX and GYKI 52466 significantly attenuates the volume of neocortical infarction in a model of tran- sient focal ischemia in hypertensive rats; NBQX treatment could be delayed by up to 90 min follow ing the onset of 2 h of ischemia and still resulted in marked cytoprotection; delayed treatment with GYKI 52466 or NBQX rescues penumbral tissue during reperfusion, but there appears to be no pro tective effect for the 100-120 mm3 of tissue judged to have been in the core of the ischemic region ir rigated by the MCA; the NMDA antagonist MK-801, when given 90 min following ischemia, had no comparable effect on infarct size in these hyperten sive rats; and a combination of the NMDA and AMP A antagonists attenuated the protective re-sponse of the latter. We have therefore demon strated that following the onset of transient focal ischemia, resulting neocortical infarction could be significantly reduced with the previously estab lished cytoprotective doses, determined from fore brain ischemic models, for both GYKI 52466 (Le Peillet et aI., 1992) and NBQX (Sheardown et aI., 1990; Buchan et aI., 1991a; Nellgard and Weiloch, 1992) . NBQX at this dose, i.e., 90 mg/kg, results in 1 f1M concentrations of NBQX in the CSF following severe forebrain ischemia in vivo, a concentration that in vitro selectively blocks AMPA receptors, blocking neither the glycine portion of the NMDA 139 ± 38a (7) The effect of delayed treatment with NBQX ± MK-801 given i. receptor nor the metabotropic receptor (L. Nord holm, personal communication). This implies that the drug is active as a selective antagonist of the AMP A receptor. Changes in intraischemic blood flow do not seem to provide the explanation for the demonstrated delayed protection with NBQX (Buchan et aI., 1991c) . Although GYKI 52466 also blocks AMPA recep tor-linked responses (Done van and Rogawski, 1993) in the concentrations used here (Tarnawa et aI., 1992) , additional protection may be afforded by its ability to prevent the presynaptic release of gluta mate (Arvin et aI., 1992) . GYKI 52466 has previ ously been demonstrated to reduce infarction fol- lowing permanent MCA occlusion (Smith and Mel drum, 1992) , and here we provide evidence that a similar effect is possible with delayed treatment in a model of transient focal ischemia, suggesting cellu lar, rather than vasoactive, protective effects. NMDA glutamate antagonists, while able to re duce infarct volume in some models using nor motensive rats, have had relatively less effect in SHRs, as is seen here and as has been previously reported (Buchan et aI., 1992a; Roussel et aI., 1992) . Pretreatment with MK-801 did, however, produce a large reduction in infarct volume in Wistar rats exposed to a similar, transient focal in sult (2 h), but in this normotensive strain, we de-6. (10 mg/kg X 5) J.P. Treatment (n) tected a marked increase in intraischemic rCBF to the core of the ischemic region that we did not de tect with pretreatment for the relatively unpro tected SHR (Buchan et aI., 1992a) . Roussel et al. (1992) were similarly unable to demonstrate infarct volume reductions with MK-801 in hypertensive, as opposed to normotensive, rat strains (Roussel et aI., 1992) . Dirnagl et aI. (1990) had to give repeated pre-and postocclusion doses of MK-801 to achieve small reductions in the size of the cortical infarct following permanent MCA occlusion in SHRs. Their infarct reductions were subsequently corre lated by Jacewicz et aI. (1991) , using e 4 C]iodoan tipyrine, to be related to increases in penumbral blood flows. A similar conclusion has been drawn from observations that the competitive NMDA an tagonist CGS 19755 also increases rCBF to the pen umbra, affording a vasoactive explanation for re duced injury and improved metabolism in the wake of permanent focal ischemia (Takizawa et aI., 1991) . Two recent studies, one with thrombotic MCA oc clusion (Yao et aI., 1993) and the other with embolic focal ischemia (Memezawa et aI., 1993) in nor motensive rats, were also unable to demonstrate that MK-801 reduced infarct volume. Both models of intraluminal occlusion produce dense ischemia, possibly interfering with any potential collateral re sponse in the perifocal areas, perhaps accounting for the failure of MK -801 to attenuate injury in these situations (Memezawa et aI., 1993; Yao et aI., 1993) . For NBQX-treated SHRs, rCBF was not af fected by delayed NBQX treatment (90 min post MCA occlusion); i.e., no rCBF changes were de tected either just before or after reperfusion in ei ther the core region or the edge (penumbra) of the ischemic cortex. In our study with GYKI 52466, there was a modest increase in rCBF at the end of 2 h of ischemia in those animals given drug at 1 h as compared with those given saline, which could in part account for the improvement in outcome.
A mechanistic explanation for NBQX's protec tion in the absence of changes in blood flow is sug gested by work in vitro that has demonstrated that glutamate excitotoxicity in culture is mediated not just by NMDA but also by non-NMDA receptors (Frandsen et aI., 1989) . While quinoxaline diones can prevent the toxicity induced by non-NMDA ag onists such as kainate or AMP A (Honore et aI., 1988) , they are relatively unsuccessful at preventing NMDA-induced cytotoxicity. Conversely, NMDA induced cytotoxicity can be prevented with 2-amino-5-phosphonovalerate but not 6-cyano-7nitroquinoxaline-2,3-dione or 6,7 -dinitroquinox aline-2,3-dione, but to prevent glutamate-related excitotoxicity it is necessary to block both the J Cereb Blood Flow Metab, Vol. 14, No.2, 1994 NMDA and the non-NMDA receptors (Frandsen et aI., 1989) . In vivo the ischemia-induced release of glutamate (Benveniste et aI., 1984) might promote calcium entry through either NMDA or non-NMDA receptors or both. Given data emerging from in vivo anoxia studies that suggest that a combination of AMPA and NMDA antagonists enhances neuropro tection (Kaku et aI., 1993) , we had hypothesized that the "cocktail" of MK-801 and NBQX might have proven to be even more efficacious than NBQX alone. To understand why the cocktail of these two potent glutamate antagonists resulted in less protection than NBQX alone, various hypoth eses can be proposed. The concurrent use of the channel blocker MK-801 might have prevented the optimal binding of NBQX to the AMP A receptor. Coadministration of both MK-801 and NBQX could affect the absorption of NBQX from the peritoneal space, resulting in less than the critical 1 ILM con centration, ordinarily reached with this dose, nec essary to block the AMP A receptor. NBQX is rel atively insoluble; its absorption from the i.p. dose ordinarily produces a smooth plasma curve with physiologically relevant concentrations achieved with only �0.5% crossing through the blood-brain barrier (L. Nordholm, personal communication), so any interference with either absorption or binding might interfere with brain concentrations necessary for neuroprotection. The combination of the drugs produced no obvious deterioration in the physiolog ical conditions and had no deleterious effect on CBF, either at the time of reperfusion or at the time of death. In our forebrain ischemia studies, the cy toprotective effect of NBQX in CAl was similarly attenuated when MK-801 was coadministered (Li and Buchan, 1993) .
Calcium ions can actually pass through both NMDA and non-NMDA or AMPA receptor-linked ionophores, previously thought of as conducting monovalent cations only (lino et aI., 1990; Gilbert son et aI., 1991; Hollmann et aI., 1991; Burnashev et aI., 1992) . Intriguing postsynaptic explanations as to how the blockade of the AMP A receptor by ei ther NBQX or GYKI 52466 attenuates injury at a cellular level have been suggested by recent molec ular studies. Hollmann et aI. (1991) and Monyer et aI. (1992) have shown that specific combinations of AMPA receptor subunits (GluRl, GluRz, GluR 3 , and GluR 4 ) are permeable to calcium ions, and cells in both retina (Gilbertson et aI., 1991) and hippo campus (lino et aI., 1990; Ogura et aI., 1990 ) do allow Ca 2 + entry through non-NMDA receptor linked channels. The critical determinant is the presence or absence of GluRz: Present GluRz blocks Ca z + currents, a property dependent on RNA editing with insertion of the polar amino acid arginine in the transmembrane portion of the AMPA-linked channel (Hume et aI., 1991; Sommer et aI., 1991; Verdoorn et aI., 1991) . Postischemic reductions in the expression of the mRNA for GluR 2 subunits in CAl neurons (Pellegrini Giampietro et aI., 1992) , or, potentially, a failure of the posttranslational RNA editing that controls AMPA channel Ca 2 + conductance (Sommer et aI., 1991) , suggests explanations for why AMPA antag onists might unexpectedly prevent Ca 2 + influx and afford cytoprotection. While correlations with re ductions in calcium influx to the cells on the edge of ischemia (penumbra) with the use of NBQX and Ca 2 + -calmodulin binding immunohistochemistry have been attempted in a permanent MCA occlu sion rat model, preliminary data suggest no differ ence in either the Ca 2 + -calmodulin binding or the infarct size with NBQX given by i. v. administration (DeGraba et aI., 1992) . Further work on the cellular mechanism of action of these two novel AMP A an tagonists is urgently needed for us to fully under stand the mechanism of action. Despite this uncertainty, protection has now been seen for these "early" or prototype AMPA antag onists in models of severe forebrain ischemia in rats (four-and two-vessel occlusion with hypotension) (Buchan et aI., 1991a; Diemer et aI., 1992; Nellgard and Wieloch, 1992; Pulsinelli and Cho, 1992) and the gerbil (Sheardown et aI., 1990) . Reduction in infarction has been observed in models of focal ischemia (both temporary and permanent MCA oc clusion) in Sprague-Dawley and SHR rats for NBQX (Buchan et aI., 1991c; Gill et al., 1992) and for GYKI 52466 for at least the temporary model in SHRs as seen here (Expt. 3) and in permanent focal ischemia in Fischer rats (Smith and Meldrum, 1992) . The ability to give these two different drugs late-NBQX has been given up to 12-24 h after global ischemia, still protecting CAl cells Li and Buchan, 1993) and, as seen here, NBQX and GYKI 52466 treatment delayed well into the focal ischemic insult-makes a strong case for their clinical relevance.
A major concern, in terms of the clinical applica tion of the competitive or polar AMP A antagonists, is their difficulty with solubility and their tendency to precipitate out of physiological solution. Al though i. v. drug infusions give comparable plasma curves to i.p. injections (L. Nordholm, personal communication), we observed only cytoprotective responses in a proportion of the i. v. infused ani mals, possibly as a result of the increased precipi tation in the tubules of the renal medulla, where Na + concentrations are hypertonic. This precipita-tion was particularly manifest with i. v. infusions as compared with the i.p. administered NBQX. This nephrotoxicity caused damage to the pyramids and, ultimately, if animals were allowed to survive, a nephropathy. If observed in other species during toxicological studies, this would clearly limit the development of NBQX as a clinical therapy. There have, as yet, been no reports as to whether these AMP A-acting drugs might cause cerebrotoxicity such as the a priori cingulate vacuolization that has been described for NMDA antagonists (Olney et aI., 1989 (Olney et aI., , 1991 .
In summary, we have shown that both of the AMP A antagonists available (NBQX and GYKI 52466) can reduce the volume of neocortical infarc tion, even when administered after a delay in a model of transient focal neocortical ischemia in hy pertensive rats. In contrast, we did not observe pro tection with delayed NMDA antagonism (MK-801), and disappointingly, the combination of NMDA and AMP A glutamate antagonists resulted in the loss of the AMPA antagonism-mediated neuroprotection. That two different agents, acting at different sites of the AMP A receptor complex (Donevan and Rogaw ski, 1993) , have induced similar degrees of neuro protection with delayed treatment paradigms lends further support to the relative importance of the AMPA receptor's role in injury acquired by the acutely ischemic brain (Buchan et aI., 1991a; Di emer et aI., 1992; Nellgard and Weiloch, 1992) .
